Research and development (R&D) in all
fields is a costly affair, but more so in bio-technology, where
molecules are first evolved, developed and then subjected to
arduous and expensive clinical trials. Till such time that the
molecule reaches the final stage, it is simply work-in-progress
(WIP), even though the idea and formulation are
valuable.
Further development of the WIP is even more expensive and needs
an even larger source of funding. To brave cash crunches and the
inherent risk of uncertainty in R&D, a common and relevant
modus operandi for many WIP technologies is to transfer such WIP
into another group company or a joint venture company. Such
transfer is intended to facilitate further fine-tuning of the WIP
until eligible for commercial exploitation, through licensing,
manufacturing, production or processing.